Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus.

Proceedings of the National Academy of Sciences of the United States of America
Sarika GuptaAvadhesha Surolia

Abstract

Diabetes is a chronic disease requiring continuous medical supervision and patient education to prevent acute secondary complications. In this study, we have harnessed the inherent property of insulin to aggregate into an oligomeric intermediate on the pathway to amyloid formation, to generate a form that exhibits controlled and sustained release for extended periods. Administration of a single dose of the insulin oligomer, defined here as the supramolecular insulin assembly II (SIA-II), to experimental animals rendered diabetic by streptozotocin or alloxan, released the hormone capable of maintaining physiologic glucose levels for >120 days for bovine and >140 days for recombinant human insulin without fasting hypoglycemia. Moreover, the novel SIA-II described here not only improved the glycemic control, but also reduced the extent of secondary diabetic complications.

References

Oct 30, 1998·Endocrine Reviews·W C DuckworthF G Hamel
Jan 14, 2005·The New England Journal of Medicine·Irl B Hirsch
Dec 24, 2005·The New England Journal of Medicine·David M NathanUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Oct 14, 2006·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey F SmithMark E Welland
Mar 2, 2010·Nature Reviews. Drug Discovery·Paul Burn
Apr 21, 2010·Nature Reviews. Cardiology·Aparna BrownDennis Bruemmer

❮ Previous
Next ❯

Citations

Dec 15, 2010·Journal of Biomolecular Structure & Dynamics·Seema Mishra
Mar 2, 2011·Diabetes Technology & Therapeutics·Saptarshi BhattacharyaSadanand Dwivedi
Nov 24, 2011·Nano Reviews·Shruti MankarSamir K Maji
Jan 3, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hao-Syun ChouDean-Mo Liu
Aug 21, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Mayura Oak, Jagdish Singh
Nov 28, 2012·Advanced Healthcare Materials·Kaitlin M BratlieDaniel G Anderson
Jun 6, 2015·Materials Science & Engineering. C, Materials for Biological Applications·Xiangde LinJinkee Hong
Dec 30, 2014·Biomaterials·Shweta PasiAvadhesha Surolia
Feb 27, 2017·Colloids and Surfaces. B, Biointerfaces·Jayakrishnapillai P VKaladhar Kamalasanan
Feb 5, 2019·Journal of Peptide Science : an Official Publication of the European Peptide Society·Shalini GourJay Kant Yadav
Feb 19, 2020·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Yuanpeng WangYongjun Zhang
Feb 27, 2020·Expert Opinion on Drug Metabolism & Toxicology·Deep DuttaSanjay Kalra
Sep 30, 2020·Chemical Communications : Chem Comm·Mohsen AkbarianVladimir N Uversky
Feb 21, 2018·International Journal of Biological Macromolecules·Md Tauqir AlamAabgeena Naeem
May 22, 2021·Biomaterials Science·Vijay KumarAshwani Kumar Thakur
Oct 22, 2011·ACS Chemical Biology·B Ruthrotha SelviTapas K Kundu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.